The Food and Drug Administration on Monday approved Biogen Alzheimer’s drug aducanumab, making it the first drug cleared by U.S. regulators to slow cognitive decline in people living with Alzheimer’s and the first new medicine for the disease in nearly two decades.
The FDA’s decision was highly anticipated. The drug, which is marketed under the name Aduhelm, is also expected to generate billions of dollars in revenue for the company.
“We are well-aware of the attention surrounding this approval,” Dr. Patrizia Cavazzoni, director of the FDA’s Center for Drug Evaluation and Research, said in a press release.
Read the full article. As I noted yesterday, the drug has faced skepticism from some experts who says its efficacy has not been conclusively proven.
BREAKING: FDA approves Biogen’s Alzheimer’s drug, the first new therapy for the disease in nearly two decades https://t.co/ZCuPGDUO9A
— CNBC Now (@CNBCnow) June 7, 2021